* Approved: Acorda (ACOR) Ampyra, MS walking. $70M; $280-500M
* Approved: Auxilium (AUXL) Xiaflex for Dupuytren’s. $24M; $400M
* Feb 12: Cadence (CADX) pain drug acetavance. $25M; $500M
* Feb 13: Gilead (GILD) CF drug Cayston (aztreonam). ?; $300M
* Feb 28: Shire (SHPGY) velaglucerase, Gaucher’s. $75M; $300M
* March 5: Amylin (AMLN), Exenatide LAR, diabetes. ?; $1.25B
* April 23: Cell Thera (CTIC) pixantrone, lymphoma. ?; $50M-$1B*
* May 1: Dendreon (DNDN) Provenge, prostate ca. $90M; $1.5B
* May 4: Intermune (ITMN) IPF drug pirfenidone. $36M; $1B
* March or July?: Amgen (AMGN) bone drug Prolia. $95M; $4B
* Late July: NicOx (COX.PA) arthritis drug naproxcinod. ?; $1.5B
* Sept 25: Human Genome (HGSI) Benlysta, lupus. $300M; $4B
* Late Oct: Shire Fabry drug Replagal. $209M; $265M
* Late Oct: Vivus (VVUS) obesity drug Qnexa. ?; $1B
* Late Oct: Orexigen (OREX) obesity drug Contrave. ?; $1B
* TBD: Arena (ARNA) obesity drug lorcaserin. ?; $850M
* TBD: MannKind (MNKD) diabetes drug Afrezza. $25M; $597M
*Note: Estimates for pixantrone sales are all over the map.